DeepMed Research

YALE UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1701-10-09

Employees: 10K

Market Cap: -

Website: http://www.yale.edu

Clinical Trials

Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer

Phase 2

Terminated

Conditions: Hormone-Sensitive Breast Cancer
Breast Cancer

Interventions: Drug: Bevacizumab
Drug: Letrozole

First Posted Date: 2007-04-18

Last Posted Date: 2021-03-16

Lead Sponsor: Yale University

Target Recruit Count: 5

Registration Number: NCT00461773

Locations: 🇺🇸
Yale University, Yale Cancer Center, New Haven, Connecticut, United States

Emergency Physician Brief Interventions for Alcohol

Not Applicable

Completed

Conditions: Hazardous Drinking
Harmful Drinking

Interventions: Behavioral: Brief Negotiation Interview (BNI)
Behavioral: Discharge Instructions

First Posted Date: 2007-03-05

Last Posted Date: 2020-03-30

Lead Sponsor: Yale University

Target Recruit Count: 500

Registration Number: NCT00443183

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States

Topical Sirolimus in Patients With Basal Cell Nevus Syndrome and in Healthy Participants

Phase 1

Completed

Conditions: Neoplastic Syndrome
Non-melanomatous Skin Cancer

First Posted Date: 2007-02-12

Last Posted Date: 2016-09-23

Lead Sponsor: Yale University

Target Recruit Count: 16

Registration Number: NCT00433485

The Effect of Protein Supplementation on Bone Health in Healthy Older Men and Women

Phase 1

Completed

Conditions: Bone Resorption
Osteoporosis

Interventions: Dietary Supplement: Whey protein supplement
Dietary Supplement: Placebo

First Posted Date: 2007-01-12

Last Posted Date: 2020-04-09

Lead Sponsor: Yale University

Target Recruit Count: 208

Registration Number: NCT00421408

Locations: 🇺🇸
University of Connecticut Health Center, Farmington, Connecticut, United States
🇺🇸
Yale University, New Haven, Connecticut, United States

Effects of Atomoxetine on Cognitive Function in Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia
Cognition
Smoking

First Posted Date: 2007-01-11

Last Posted Date: 2007-12-12

Lead Sponsor: Yale University

Target Recruit Count: 12

Registration Number: NCT00420498

Locations: 🇺🇸
Connecticut Mental Health Center, SAC-115, New Haven, Connecticut, United States

Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets

Phase 3

Completed

Conditions: Hypophosphatemia, Familial
Hyperparathyroidism

Interventions: Drug: Paricalcitol
Other: Placebo

First Posted Date: 2007-01-01

Last Posted Date: 2020-03-17

Lead Sponsor: Yale University

Target Recruit Count: 33

Registration Number: NCT00417612

Locations: 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

Craving, Binge Eating and Obesity

Phase 2

Completed

Conditions: Binge Eating Disorder
Obesity

Interventions: Other: Placebo
Drug: bupropion

First Posted Date: 2006-12-21

Last Posted Date: 2020-04-03

Lead Sponsor: Yale University

Target Recruit Count: 61

Registration Number: NCT00414167

Locations: 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth

Not Applicable

Completed

Conditions: Impaired Glucose Tolerance
Type 2 Diabetes Mellitus
Obesity

Interventions: Drug: Rosiglitazone
Drug: Placebo

First Posted Date: 2006-12-19

Last Posted Date: 2013-07-22

Lead Sponsor: Yale University

Target Recruit Count: 21

Registration Number: NCT00413335

Locations: 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States

A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Rapamycin
Drug: Trastuzumab

First Posted Date: 2006-12-15

Last Posted Date: 2016-09-21

Lead Sponsor: Yale University

Target Recruit Count: 11

Registration Number: NCT00411788

Locations: 🇺🇸
Yale Comprehensive Cancer Center at Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸
Bridgeport Hospital, Bridgeport, Connecticut, United States

A Phase I/II, Multi-Center, Open-Label, Dose-Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients With Advanced Pancreatic Carcinoma

Phase 1

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Capecitabine
Drug: PHY906

First Posted Date: 2006-12-15

Last Posted Date: 2015-03-27

Lead Sponsor: Yale University

Target Recruit Count: 25

Registration Number: NCT00411762

Locations: 🇺🇸
Yale Comprehensive Cancer Center at Yale University School of Medicine, New Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy